Effectiveness of Switching to Darunavir/Cobicistat in Virologically Suppressed HIV-Positive Patients Receiving Ritonavir-Boosted Protease Inhibitor-Based Regimen: The "STORE" Study: Journal of acquired immune deficiency syndromes (1999)

A. Gori, A. Antinori, A. Vergori, M.V. Cossu, B. Menzaghi, G. Sterrantino, S. Rusconi, A.M. Cattelan, F. Castelli, N. Gianotti, G. Orofino, D. Ripamonti, S. Savinelli, E. Manzillo, T.A. Santantonio, B.M. Celesia, R. Cauda, R. Maserati, A. dʼArminio Monforte, C. StingoneS. Bonora, A. Uglietti, R. Termini, F. Rucci, D. Mancusi

Research output: Contribution to journalArticlepeer-review

Abstract

OBJECTIVE: This study investigates the effectiveness and tolerability of switching to a darunavir/cobicistat (DRV/c)-based antiretroviral regimen from a ritonavir-boosted protease inhibitor (PI/r)-based regimen in virologically suppressed HIV-positive patients. DRV trough values were also investigated. SETTING: Prospective, multicenter, single-country, noninterventional cohort study. METHODS: This study included patients on a PI/r-based ART for at least 12 months having plasma HIV-1 RNA <50 copies/mL since at least 6 months. The primary endpoint, defined as HIV-1 RNA <50 copies/mL, was measured at 48 ± 6 weeks from baseline. A secondary analysis was performed using the time to loss of virological response algorithm. Biochemical parameters, including DRV trough samples, were collected as per clinical practice and measured using high-performance liquid chromatography. RESULTS: Of 336 patients enrolled, 282 completed the study: 70.8% had plasma HIV-1 RNA <50 copies/mL at 48 weeks; using the time to loss of virological response algorithm, 82.7% maintained virological suppression. Virological failure was observed in 6 patients (1.8%). Adverse event-related discontinuations were 4.5%. After 48 weeks, we found a significant improvement in both triglycerides (median, 130 to 113.5 mg/dL, P = 0.0254) and high-density lipoprotein cholesterol (48 to 49 mg/dL, P < 0.0001) but no change in other biomarkers. DRV trough concentrations in 56 subjects showed a median value of 2862.5 (1469.5-4439) ng/mL, higher in women than in men (4221 vs. 2634 ng/mL, P = 0.046). CONCLUSIONS: In stable HIV-1 positive virologically suppressed patients, the switch to DRV/c-based ART was beneficial in terms of low rates of virological failure and adverse events due to its high tolerability and improvement in triglycerides.

Original languageEnglish
Pages (from-to)290-294
Number of pages5
JournalJ. Acquir. Immune Defic. Syndr.
Volume84
Issue number3
DOIs
Publication statusPublished - Jul 1 2020

Fingerprint

Dive into the research topics of 'Effectiveness of Switching to Darunavir/Cobicistat in Virologically Suppressed HIV-Positive Patients Receiving Ritonavir-Boosted Protease Inhibitor-Based Regimen: The "STORE" Study: Journal of acquired immune deficiency syndromes (1999)'. Together they form a unique fingerprint.

Cite this